AbCellera Biologics Inc (ABCL)

NASDAQ

$5.80

AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.

Sector:

Industry:

68 analysts

Buy

Target: $10.50 (+81.03%)

Market Cap

$2.05B

Free Cash Flow Yield

-9.24%

Beta (5Y)

1.66

Adjust inflation

Log

Valuation

Market Cap$2.05B

Forward P/E27.55

P/S25.99

P/B2.19

Profitability

Total Revenue (TTM)$79M

Gross Profit (TTM)-$112M

EBITDA-$192M

Profit Margin-181.7%

Operating Margin-692%

EPS-$0.48

Financial Health

Free Cash Flow Yield-9.24%

Growth & Risk

Revenue 5Y CAGR-28.75%

Beta (5Y)1.66

Sharpe Ratio0.84